About

Kimberly-Clark Projects Q3 Sales Dip but Holds 2026 Outlook Amid China Huggies Rumors

Published
Score
10

Why it matters

Kimberly-Clark's October 15, 2026 preliminary third-quarter filing estimated net sales of $4.134 billion, down 0.4% from $4.150 billion a year earlier. Organic sales fell 1.3%, reversing 2.5% growth in the prior-year quarter. The company reaffirmed full-year 2026 guidance and blamed the shortfall mainly on disruption tied to social media activity in China, which it said could cut overall growth by about one percentage point. Adjusted EPS from continuing operations was $1.70, above the $1.60 consensus. The problem began in June, when Chinese social-media posts claimed Huggies diapers contained formamide, just before the "618" shopping festival. Babycare and Bibabebe faced similar accusations. Kimberly-Clark cited third-party testing that confirmed its products' quality and safety. On June 22, China's market regulator said it had formed a joint investigation team into "formamide issues in infant diapers" without naming any company. On August 4, the company cut its annual forecasts. It now expects 2026 organic sales growth to trail the weighted average growth of its categories and markets by about 100 basis points, down from its earlier expectation of in-line growth. Second-quarter revenue of $4.19 billion, up 0.6%, missed the $4.22 billion FactSet analyst forecast.

Coverage of the October update disagrees on the cause of the sales decline. One newsletter estimates the China social-media drag at roughly 250 basis points on third-quarter organic sales, compared with about 100 basis points for the full year, and also cites a California distribution-center fire and freight costs as margin pressures. A separate report says Chinese authorities found no formamide in the company's products. The date and official source of that finding are not yet established, and the regulator's broader investigation has not been publicly resolved.

Attorneys should watch the final third-quarter results on November 5 for whether the China drag stays near the 100-basis-point full-year estimate or deepens. The outcome matters for the roughly $40 billion Kenvue acquisition, which remains on track to close by year-end. Reuters quoted an analyst warning that a prolonged reputational problem could delay market share recovery even after regulators close their investigation. Any formal findings from China's regulator, or a public resolution of the investigation, should be treated as the key trigger for reassessing the company's exposure.

Sources

mail Subscribe to M & A email updates

Primary sources. No fluff. Straight to your inbox.

Related

View all M & A

Also on LawSnap